“…In contrast, in placebo-controlled studies of patients with mild-to-moderate vascular dementia, a complex disorder in which the cholinergic system is also compromised (Gratham and Geerts, 2002), memantine caused a small, albeit significant, cognitive improvement that was not clinically perceived, given that it was not accompanied by amelioration of the global clinical impression of change (Wilcock, 2003). Furthermore, there is evidence that, resembling nicotinic antagonists (Levin, 2002), memantine impairs cognition in laboratory animals (Willmore et al, 2001) and healthy human subjects (Schugens et al, 1997). In particular, a single dose of memantine (30 mg) administered orally to young, healthy humans impairs the eyeblink classical conditioning (Schugens et al, 1997), a form of associative learning that is modulated by the nicotinic cholinergic system and differentiates cognitive deficits in normal aging and probable AD (Woodruff-Pak, 2001).…”